Insmed (INSM) Soars on Bargain-Hunting After 10-Month Low

Insmed Incorporated (NASDAQ:INSM) is one of the 10 Stocks With Stunning Gains.

Insmed climbed by 11.66 percent on Tuesday to close at $116 apiece, as investors resorted to bargain-hunting after touching a 10-month low the day prior.

On Monday, it can be recalled that the stock fell below the $100 territory, touching $98.90 at intra-day trading—its lowest price over the last 10 months, dented by an earnings miss in the first quarter of the year.

Photo from Insmed website

Investors, however, took the drop as an opportunity to hunt for bargains on Tuesday, with Insmed Incorporated (NASDAQ:INSM) maintaining a “strong buy” recommendation from 16 analysts.

In the first quarter of the year, Insmed Incorporated (NASDAQ:INSM) slashed its net loss by 36 percent to $163 million from $256 million in the same period last year, as total revenues soared by 230 percent to $306 million from $92.8 million year-on-year, thanks to strong sales from its lung treatment, Brinsupri.

The therapy alone raked in $207.2 million in sales in the US, and $700,000 internationally.

“The trajectory of the Brinsupri launch continues to exceed our expectations, and we are especially encouraged by the positive topline results from the Encore Phase 3b study, which could enable us to extend our reach to even more patients. We remain focused on improving bronchiectasis diagnosis, expanding the Arikayce label, advancing our Phase 3 programs for TPIP, and progressing our early-stage pipeline, with the ambition of delivering meaningful innovation and improving the lives of patients with serious diseases,” said Insmed Incorporated (NASDAQ:INSM) CEO Will Lewis.

In other news, the company is set to present data from the Phase 3b study for Arikayce at the American Thoracic Society International Conference 2026 on May 17 to 20.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.